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During heart transplantation, storage in cold preservation solution is thought 32 
to protect the organ by slowing metabolism; by providing osmotic support; and by 33 
minimising ischaemia-reperfusion (IR) injury upon transplantation into the 34 
recipient1,2. Despite its widespread use our understanding of the metabolic changes 35 
prevented by cold storage and how warm ischaemia leads to damage is surprisingly 36 
poor. Here, we compared the metabolic changes during warm ischaemia (WI) and 37 
cold ischaemia (CI) in hearts from mouse, pig, and human. We identified common 38 
metabolic alterations during WI and those affected by CI, thereby elucidating 39 
mechanisms underlying the benefits of CI, and how WI causes damage. Succinate 40 
accumulation is a major feature within ischaemic hearts across species, and CI slows 41 
succinate generation, thereby reducing tissue damage upon reperfusion caused by 42 
the production of mitochondrial reactive oxygen species (ROS)3,4. Importantly, the 43 
inevitable periods of WI during organ procurement led to the accumulation of 44 
damaging levels of succinate during transplantation, despite cooling organs as 45 
rapidly as possible. This damage was ameliorated by metabolic inhibitors that 46 
prevented succinate accumulation and oxidation. Our findings suggest how WI and 47 
CI contribute to transplant outcome and indicate new therapies for improving the 48 
quality of transplanted organs. 49 
Hearts are transplanted following donation after brainstem death (DBD), or 50 
following donation after circulatory death (DCD)5-8. Cooling the heart at the onset of 51 
ischaemia remains the mainstay of organ preservation, although emerging technologies 52 
allow preservation of some organs under normothermic and/or normoxemic conditions8,9. 53 
Rapid cooling minimises periods of WI during transplantation, which causes primary 54 
graft non-function, delayed or poor initial graft function, or chronic graft dysfunction10,11. 55 
Here we investigated the metabolic alterations during WI that contribute to tissue injury 56 
upon transplantation and which are prevented by CI.  57 
We compared the metabolic profile of mouse hearts and in sections of pig and 58 
human myocardium under conditions that mimic cold organ storage during 59 
transplantation (CI; ~2˚C) and compared these with WI (37˚C) (Fig. 1a) over time. There 60 
was a much faster decline in ATP/ADP ratio during WI compared to CI in all three 61 
species (Fig. 1b-d), decreasing by over 50% during the first 5 min of WI while 5 min of 62 
 3
CI had a negligible effect. In CI heart contraction ceased within ~1–2 s, but in WI 63 
contraction continued for ~90 s, however ATP consumption by contraction during WI did 64 
not contribute to changes in ATP/ADP as preventing contraction by cardioplegia did not 65 
affect the ATP/ADP ratio (Supplementary Fig. 1a). The total amount of ATP and ADP 66 
(ΣATP + ADP) was also better maintained during CI than WI (Figs. 1e-g), while AMP 67 
accumulation was faster during WI than in CI (Supplementary Fig. 1b). Thus, CI 68 
preserves the tissue ATP/ADP ratio and slows the loss of adenine nucleotides. 69 
During ischaemia oxidative phosphorylation stops and glucose is no longer 70 
delivered by the blood, hence the ATP/ADP ratio is sustained by glycogen-fuelled 71 
glycolysis12, generating lactate (Supplementary Fig. 2a). Glycogen in the mouse and pig 72 
was more rapidly depleted during WI, but depletion halted, despite 20–25 % of the 73 
glycogen remaining (Supplementary Figs. 2b,c). During CI glycogen depletion was 74 
slower, but continued until all the glycogen was consumed (Supplementary Figs. 2b,c). 75 
During WI lactate initially accumulated but then plateaued, whereas during CI the rate of 76 
lactate build up was far slower, but continued throughout CI (Supplementary Figs. 2d-h). 77 
In the mouse lactate accumulation ceased when glycogen breakdown stopped (dashed red 78 
line; Supplementary Figs. 2b,d). The lactate/pyruvate and NADH/NAD+ ion intensity 79 
ratios both increased far more rapidly and extensively during WI than during CI in the 80 
mouse (Supplementary Figs. 2h,i). Measurement of glycolytic intermediates in the mouse 81 
heart showed an accumulation of the GAPDH substrate glyceraldehyde-3-phosphate 82 
during WI, but the loss of products downstream of 3-phosphoglycerate kinase, 3-83 
phosphoglycerate and phosphoenolpyruvate compared to CI (Supplementary Fig. 3). 84 
These two enzymes utilise NAD+ and ADP and thus are likely inhibited by an elevated 85 
NADH/NAD+ ratio and depletion of ADP (Supplementary Fig. 2a). This may slow 86 
glycolysis during WI, even though glycogen stores remain. Thus, during WI there was 87 
rapid glycogen depletion to drive glycolysis, which was slowed by CI.  88 
To assess ischaemic metabolism more broadly, we performed a liquid 89 
chromatography/mass spectrometry (LC/MS)-based metabolomics analysis of mouse, pig 90 
and human heart tissue at various times under CI and WI (Supplementary Tables 1a-c). 91 
Fifty-four metabolites were detected ubiquitously at up to 30 min WI and 480 min CI and 92 
changes in their abundance are presented as a heat map, demonstrating a similar overall 93 
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profile in mouse, pig and human heart tissue (Supplementary Fig. 4). We expanded the 94 
metabolome coverage to 107 metabolites for the mouse samples by a second LC/MS 95 
analysis which generated an extended heat map (Supplementary Fig. 5).  96 
To compare how these metabolites changed between WI and CI (Supplementary 97 
Table 2) we generated volcano plots for mouse, pig and human heart tissue (Figs. 2a-c). 98 
Strikingly, most of the significant metabolic changes between WI and CI at the 30-min 99 
time point were comparable between mouse, pig and human hearts (red and green 100 
symbols). The only metabolites that changed in qualitatively different ways between 101 
species were fumarate and malate (Supplementary Table 1), which both accumulated 102 
during WI in the pig, decreased in the mouse and showed minor changes in the human. 103 
As can be seen there were notable and similar changes in many metabolites for all three 104 
species, including for choline, nicotinamide, alanine, proline, aconitate, branched chain 105 
amino acids and in the breakdown products of purines and pyrimidines.  106 
Succinate increased dramatically during WI in all species (Figs. 2a-c). This 107 
finding was of particular interest because succinate accumulation during ischaemia 108 
contributes to IR injury upon reperfusion via generation of ROS by reverse electron 109 
transport (RET) at mitochondrial complex I3,4. Quantification of succinate levels over 110 
time showed that during WI there was rapid succinate accumulation within 6 min that 111 
increased further and plateaued at about 30 min (Figs. 3a–c). During CI succinate 112 
accumulation was far less, and even after 4h CI — the storage limit for human hearts to 113 
be transplanted — succinate was less than after 6 min WI (Figs. 3a-c). Even after 114 
extending CI of mouse hearts to 12 h the succinate level was still similar to that after 12 115 
min of WI (Fig. 3d). The relative changes (Figs. 3a-c) as well as the absolute succinate 116 
levels (Fig. 3e) were remarkably similar in mouse, pig and human heart tissue. 117 
Cardioplegia slightly decreased succinate levels during WI in the mouse hearts 118 
(Supplementary Fig. 6a), but even so the relative accumulation was still 4 –5-fold above 119 
CI levels, suggesting that succinate accumulation is unrelated to changes in muscle 120 
contraction. As succinate accumulation is driven by the interconversion of fumarate and 121 
succinate by succinate dehydrogenase (SDH) we next assessed the succinate/fumarate ion 122 
intensity ratio (Figs. 3f-h). This showed a significant increase during WI in mouse, with a 123 
less pronounced increase in pig and human, that in all cases were slowed by CI. We 124 
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conclude that there is a significant accumulation of succinate during WI in mouse, pig 125 
and human hearts that is greatly slowed by cooling.  126 
Succinate accumulation in ischaemic mouse hearts was proportional to 127 
temperature (Supplementary Fig. 6b). When a mouse heart was transferred to cold static 128 
storage its temperature dropped to ~2˚C within 1 min (Supplementary Fig. 6c), likely 129 
minimising succinate accumulation. However, the much larger human heart (~300 g vs 130 
~150 mg for the mouse) will take far longer to cool during transplantation, potentially 131 
leading to succinate accumulation due to WI. To assess this we measured the core and the 132 
surface temperatures of a pig heart (~300 g) during flushing with cold preservation 133 
solution via the aortic root cannula immediately after cross clamp in conjunction with 134 
topical application of ice ‘slush’ (Fig. 4a), as occurs during human heart transplantation. 135 
The core took ~15 min to reach 4 ˚C, despite using the same rapid cooling procedures 136 
used during clinical heart transplantation. This slow cooling led to significant succinate 137 
accumulation (Fig. 4b). Therefore, the inevitable periods of WI during organ retrieval, 138 
cooling and storage during transplantation will lead to significant succinate accumulation.  139 
Measuring mouse heart temperature during retrieval for transplantation indicated 140 
that after the blood supply was stopped, the organ cooled slowly while the vessels were 141 
being prepared for transplantation, despite frequent topical application of cold saline 142 
(Supplementary Fig. 6d). This period of ischaemia as the organ cooled led to succinate 143 
accumulation that was retained during subsequent cold storage (Supplementary Fig. 6e). 144 
To determine whether the accumulated succinate could contribute to tissue damage by 145 
driving IR injury upon reperfusion during transplantation, we used a mouse model of 146 
syngeneic transplantation, in which a heart is transplanted heterotopically into the 147 
abdomen13,14. During transplantation, there is a further period of ~20 min ischaemia as 148 
the heart is anastomosed to the blood vessels in the recipient mouse. During this time the 149 
heart gradually warmed up, despite cooling by topical saline, leading to a further 150 
accumulation of succinate (Fig. 4c). Within 5 min of reperfusion following 151 
transplantation the succinate level returned to baseline (Fig. 4c). Therefore during 152 
retrieval, storage and transplantation donor hearts accumulate succinate that is rapidly 153 
oxidised upon reperfusion in the recipient.  154 
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To model the slower cooling of a human heart during retrieval, we then assessed 155 
whether increasing the duration of WI (in addition to the ~8 min during retrieval and the 156 
~20 min during anastomosis in the recipient) contributed to damage upon transplantation 157 
(Fig. 4d). Hearts did not survive transplantation when exposed to more than ~12 min WI 158 
after retrieval. Hearts transplanted after a further 12 min WI had increased damage 159 
evaluated 24 h after transplantation by release of troponin (Fig 4e) and mtDNA15,16 (Figs. 160 
4f,g) and by damage to mtDNA within the tissue (Fig. 4h). As the extra period of WI will 161 
increase succinate levels (Fig. 4c), these findings are consistent with increased WI 162 
contributing to heart damage through elevated succinate driving mitochondrial ROS 163 
production upon reperfusion. However, many other factors may contribute to tissue 164 
damage in addition to succinate. Therefore, we next explored the role of succinate 165 
accumulation alone in the absence of other confounding factors associated with WI. 166 
To assess the role of succinate accumulation on heart damage upon 167 
transplantation independently of other effects of WI, we increased heart succinate levels 168 
by infusing bis-acetoxymethyl succinate (AMS)17. AMS generates succinate within cells 169 
that can then be oxidised by SDH17. Hearts were incubated at 37˚C for 20 min, to mimic 170 
the time taken for anastomosis of the heart in the recipient, followed by 30 min CI. 171 
Addition of AMS after CI greatly increased tissue succinate levels above that due to WI 172 
alone due to enhanced hydrolysis of AMS at 37˚C (Supplementary Fig. 6f). AMS-treated 173 
hearts exhibited increase damage upon transplantation, as measured 24 h later by the 174 
release of troponin (Fig. 4e) and mtDNA (Figs. 4f,g) and by damage to mtDNA within 175 
the transplanted heart (Fig. 4h). Infusion of the same amount of bis-acetoxymethyl 176 
fumarate, which readily delivers fumarate within cells (Supplementary Figs. 6g),  did not 177 
lead to damage (Supplementary Figs. 6h,i), indicating that disruption to cardiac damage is 178 
specific to succinate over other TCA cycle intermediates. These findings show that 179 
succinate alone is sufficient to cause extensive damage to the transplanted heart. This is 180 
consistent with succinate accumulation being responsible for at least part of the increased 181 
heart damage caused by 12 min further WI.  182 
Finally, to determine if this increased heart damage due to 12 min further WI was 183 
decreased by inhibiting succinate accumulation and oxidation, we infused dimethyl 184 
malonate (DMM) prior to initiating retrieval and cold storage to load the heart with 185 
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malonate (Fig. 4d, Supplementary Fig. 6j). Hydrolysis of DMM will generate the SDH 186 
inhibitor malonate within the tissues slowing both the accumulation of succinate during 187 
ischaemia (Supplementary Fig. 6k) and its oxidation upon reperfusion, thereby protecting 188 
against IR injury4,18,19. DMM protected the heart against damage measured 24 hours after 189 
transplantation (Figs. 4e-h). Thus, succinate accumulation during WI and its oxidation 190 
upon reperfusion is a significant contributor to IR injury in transplantation and its 191 
amelioration decreases organ injury.  192 
We can draw a number of significant conclusions from our assessment of 193 
metabolic changes during WI and CI in mouse, pig, and human heart. Firstly, metabolism 194 
during WI and CI was comparable between mice, pigs and human hearts, encouraging the 195 
development of therapies using animal models. Secondly, during WI there was a dramatic 196 
decrease in the ATP/ADP ratio that is slowed by CI. The fall in ATP/ADP ratio during 197 
WI was paralleled by the generation of AMP via adenylate kinase, leading to AMP 198 
breakdown and an accumulation of purine and pyrimidine breakdown products. Therefore 199 
a major benefit of CI is preserving the ATP/ADP ratio and preventing loss of adenine 200 
nucleotides, the loss of which likely contributes to increased RET at reperfusion20. 201 
Thirdly, there was a rapid decrease in glycogen with WI and an associated increase in 202 
lactate, consistent with anaerobic glycolysis driving ATP production. This loss of 203 
glycogen and production of lactate was far faster in WI than CI, but interestingly there 204 
was incomplete breakdown of glycogen in WI, suggesting that the rising NADH/NAD+ 205 
ratio and/or the falling ADP level slowed glycolysis and glycogenolysis. Finally, and 206 
most interestingly, succinate accumulated very rapidly in all species during WI. 207 
Ischaemic succinate accumulation most likely arises as a consequence of the build-up of 208 
NADH and other metabolites contributing to succinate  generation by reversal of SDH3,4. 209 
However, further work will be required to assess whether glutaminolysis also contributes 210 
to succinate accumulation during WI, as recently proposed21. This selective accumulation 211 
of succinate over other TCA metabolites during ischaemia may be the consequence of 212 
multiple metabolic reactions that converge on succinate, which cannot be metabolised 213 
further under these conditions, in contrast to other TCA metabolites. 214 
Importantly, succinate accumulation occurred when we simulated donation after 215 
brain stem death (DBD) in which normoxaemic organs are cooled in situ immediately 216 
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after cessation of circulation and are therefore often considered to be exposed to ‘cold 217 
ischaemia’ only. However, these organs are exposed to at least a few minutes of ‘warm 218 
ischaemia’ as the organs become ischaemic and cooling commences, but before the organ 219 
reaches ~2°C. Thus damage caused by WI is an inevitable, albeit not widely recognised, 220 
part of all transplantation despite the widespread reliance on cold flush and storage to 221 
enhance organ preservation.  222 
In summary, in the first application of detailed and time-resolved metabolomics to 223 
transplant surgery we have shown that succinate accumulation is an important but 224 
underappreciated cause of pathology during organ transplantation. We propose that 225 
preventing the accumulation and oxidation of succinate during transplantation with new 226 
therapies and changes in methodology to ensure more rapid cooling will improve the 227 
outcome of transplantation. 228 
 229 
References  230 
1. Jahania, M. S., Sanchez, J. A., Narayan, P., Lasley, R. D. & Mentzer, R. M., Jr. 231 
Heart preservation for transplantation: principles and strategies. Ann. Thorac. 232 
Surg. 68, 1983-1987 (1999). 233 
2. Southard, J. H. & Belzer, F. O. Organ preservation. Annu Rev Med 46, 235-247 234 
(1995). 235 
3. Chouchani, E. T. et al. A unifying mechanism for mitochondrial superoxide 236 
production during ischemia-reperfusion injury. Cell Metab. 23, 254-263,(2016). 237 
4. Chouchani, E. T. et al. Ischaemic accumulation of succinate controls reperfusion 238 
injury through mitochondrial ROS. Nature 515, 431-435 (2014). 239 
5. Pagani, F. D. Use of heart donors following circulatory death: A viable addition to 240 
the heart donor pool. J. Am. Coll. Cardiol. 73, 1460-1462 (2019). 241 
6. Johnson, R. J., Bradbury, L. L., Martin, K. & Neuberger, J. Organ donation and 242 
transplantation in the UK-the last decade: a report from the UK national transplant 243 
registry. Transplantation 97, S1-S27 (2014). 244 
7. Chew, H. C. et al. Outcomes of donation after circulatory death heart 245 
transplantation in australia. J. Am. Coll. Cardiol. 73, 1447-1459 (2019). 246 
8. Dhital, K. K. et al. Adult heart transplantation with distant procurement and ex-247 
vivo preservation of donor hearts after circulatory death: a case series. Lancet 248 
385, 2585-2591 (2015). 249 
9. Nasralla, D. et al. A randomized trial of normothermic preservation in liver 250 
transplantation. Nature, 557, 50-56 (2018). 251 
10. Coffey, J. C. et al. The influence of functional warm ischemia time on DCD liver 252 
transplant recipients' outcomes. Clin. Transplant. 31, e13068 (2017). 253 
11. Blok, J. J. et al. Longterm results of liver transplantation from donation after 254 
circulatory death. Liver Transplant. 22, 1107-1114 (2016). 255 
 9
12. Eltzschig, H. K. & Eckle, T. Ischemia and reperfusion--from mechanism to 256 
translation. Nat. Med. 17, 1391-1401 (2011). 257 
13. Liu, F. & Kang, S. M. Heterotopic heart transplantation in mice. J Vis. Exp. 6, 238 258 
(2007). 259 
14. Niimi, M. The technique for heterotopic cardiac transplantation in mice: 260 
experience of 3000 operations by one surgeon. J. Heart Lung Transplant. 20, 261 
1123-1128 (2001). 262 
15. Zhang, Q. et al. Circulating mitochondrial DAMPs cause inflammatory responses 263 
to injury. Nature 464, 104-107 (2010). 264 
16. Nakahira, K. et al. Circulating mitochondrial DNA in patients in the ICU as a 265 
marker of mortality: derivation and validation. PLoS Med. 10, e1001577 (2013). 266 
17. Ehinger, J. K. et al. Cell-permeable succinate prodrugs bypass mitochondrial 267 
complex I deficiency. Nat. Commun. 7, 12317 (2016). 268 
18. Valls-Lacalle, L. et al. Selective Inhibition of succinate dehydrogenase in 269 
reperfused myocardium with intracoronary malonate reduces infarct size. Sci. 270 
Rep. 8, 2442 (2018). 271 
19. Valls-Lacalle, L. et al. Succinate dehydrogenase inhibition with malonate during 272 
reperfusion reduces infarct size by preventing mitochondrial permeability 273 
transition. Cardiovasc. Res. 109, 374-384 (2016). 274 
20. Bundgaard, A. et al. Metabolic adaptations during extreme anoxia in the turtle 275 
heart and their implications for ischemia-reperfusion injury. Sci. Rep. 9, 2850, 276 
(2019). 277 
21. Zhang, J. et al. Accumulation of succinate in cardiac ischemia primarily occurs 278 
via canonical krebs cycle activity. Cell Rep. 23, 2617-2628 (2018). 279 
 280 




Materials. The composition of UW storage solution used is (mM): potassium 284 
lactobionate, 50; KH2PO4, 25; MgSO4, 5; raffinose, 30; adenosine, 5; glutathione, 3; 285 
allopurinol, 1; and hydroxyethyl starch (50 g/L). The composition of St Thomas’s 286 
cardioplegia solution is: (NaCl 110.0 mM, NaHCO3 10.0 mM, KCl 16.0 mM, MgCl2 287 
16.0 mM, CaCl2 1.2 mM, pH 7.8). Dimethyl malonate was from Thermo Fisher 288 
Scientific, UK. Tissue samples were incubated in polypropylene tubes,  either 1.5 ml 289 
(Ref:72.690.001) or 50 mL (Ref: 62.547.004), both from  Sarstedt, Nümbrecht, Germany. 290 
 291 
Animals. C57BL/6 mice (null for transhydrogenase) were purchased from Charles River 292 
Laboratories. Mice were maintained in specific-pathogen-free animal facilities with ad 293 
libitum access to food and water. Large white male (Landrace) pigs (45-55 kg) were 294 
supplied by Envigo and were acclimatised for a minimum of 7 days prior to experiments, 295 
with ad libitum access to food and water. All animal experiments were approved by the 296 
UK Home Office under the Animals (Scientific Procedures) Act 1986. Mouse 297 
experiments were covered by PPL 80/2638.  298 
 299 
Human tissue. Heart biopsies were taken from deceased human DBD donors deemed 300 
unsuitable for cardiac transplantation aged 36-69 (Table S1). Ethical approval for the 301 
studies was obtained from NRES Committee East of England – Cambridge South (REC 302 
Reference 15/EE/0152). 303 
 304 
Mouse heart experiments. C57BL/6 mice (female) were anaesthetised with isoflurane 305 
(Abbott Laboratories, US) 2 MAC and O2 at 2 L/min. Heparin (100 µL bolus (25 iU) Leo 306 
Pharma A/S, Ballerup, Denmark) was administered intravenously into the inferior vena 307 
cava (IVC) prior to retrieval. Hearts were excised by division of the major vessels. To 308 
measure metabolite concentrations in the heart under baseline conditions in vivo, the still-309 
beating heart of an anesthetised mouse was rapidly frozen using Wollenberg clamps at 310 
liquid nitrogen (LN2) temperature, taking < 5 s to go from the beating heart to frozen. For 311 
cold ischemia (CI) the heart was placed directly in UW solution at ~2°C. Under these 312 
conditions the ventricles pulsed once or twice before stopping. For warm ischaemia (WI) 313 
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the excised heart was left in the abdomen of the animal, with the abdominal wound 314 
closed and the animal maintained on a 37°C heating pad with a relayed rectal temperature 315 
probe. For analysis at various times the whole heart was clamped at LN2 temperature as 316 
above. At various times the tissues were rapidly snap-frozen and stored at -80˚C until 317 
analysis. Fully oxygenated ‘normoxic’ heart tissue, snap-frozen immediately upon 318 
cessation of circulation, was used as control. Tissues were stored at -80°C until extraction 319 
and analysis. 320 
To replicate heart retrieval with retrograde flushing of the coronary vessels during 321 
retrieval (Supplementary Fig. 4e) the donor animal was prepared as described above. 322 
Following exsanguination, the great vessels were prepared for implantation using 323 
techniques previously described22. 500 µL Soltran® (Baxter Healthcare) was then injected 324 
via a fine bore (0.28 x 0.165 mm) polyethene tube (Portex tubing, Smith Medical 325 
International Ltd, UK) into the aorta to antegrade flush the coronary arteries. The 326 
prepared hearts were then placed in UW solution at ~2°C for various durations of CI after 327 
which, the whole heart was clamped at LN2 temperature as above. For other mouse heart 328 
experiments, a 500 µL bolus of St Thomas’ Cardioplegia solution was administered by 329 
IVC injection. Complete cessation of a heart beat was observed visually within 2 seconds. 330 
Dimethyl malonate (DMM) was administered as an infusion over 10 minutes via the IVC 331 
by a microinfusion pump (Kd Scientific, Holliston, MA, USA) using a fine bore (0.28 x 332 
0.165 mm) polyethene tube (Portex tubing, Smith Medical International Ltd, UK) prior to 333 
the administration of cardioplegia. Control animals were infused with 0.9% w/v sodium 334 
chloride by microinfusion pump (Kd Scientific, Holliston, MA, USA). 335 
Bis(acetoxymethyl)succinate (with 5% DMSO)  or bis(acetoxymethyl)fumarate (with 336 
30% DMSO)  was administered in the cardioplegia solution. Hearts from donor mice 337 
were transplanted heterotopically into a syngeneic recipient using techniques previously 338 
described13,14. In summary, end to side anastomoses of the donor ascending aorta to the 339 
recipient descending aorta, and the donor pulmonary artery to the recipient IVC were 340 
performed using microsurgical techniques. All transplanted hearts contracted 341 
spontaneously following reperfusion. Hearts were excised by division of the anastomosed 342 
vessels at chosen time points after reperfusion and the hearts were snap frozen using a 343 
Wollenberg clamp and stored at -80°C until tissue extraction. Animals were randomly 344 
 12
allocated to control and treatment groups and the analysis performed blinded to the 345 
experimental groups. 346 
 347 
Pig heart experiments. Pigs were pre-medicated with intramuscular ketamine (10 348 
mg.kg-1), medetomidine (0.02 mg.kg-1) and midazolam (0.1 mg.kg-1). A peripheral 349 
intravenous catheter was placed in the marginal ear vein and anaesthesia was induced 350 
with propofol. Pigs were intubated and 100% oxygen supplied with intermittent positive 351 
pressure ventilation provided to maintain normocapnia. Anaesthesia was maintained with 352 
continuous infusions of propofol (starting at 10 mg.kg-1hr-1 and titrating down to effect) 353 
and either remifentanil (starting at 2.4 µg.kg-1hr-1 and titrating up to effect) or alfentanil 354 
(starting at 30 µg.kg-1hr-1 and titrating up to effect). If required, isoflurane was provided 355 
at approximately 2% to maintain anaesthesia. Saline was administered intravenously at 356 
approximately 10 ml.kg-1hr-1. During anaesthesia a Datex Ohmeda Cardiocap patient 357 
monitoring system was used to monitor ECG waveform, pulse oximetry, temperature and 358 
capnography parameters. Immediately following euthanisation (induced rapidly with an 359 
overdose of approximately 200 mg.kg-1 pentobarbitone) the thoracic cavity was accessed 360 
through the diaphragm and the apex of the heart (~20-30 g) was amputated with a scalpel 361 
under terminal anaesthesia. We note that this retrieval procedure, particularly the use of 362 
anaesthesia is unavoidable, but is slightly different from that used in human 363 
transplantation. A full thickness tissue sample (~120 mg) was immediately clamped 364 
frozen using Wollenberger clamps at LN2 temperature, taking < 5 s from cessation of 365 
aortic pulse to freezing. The rest of the tissue was cut in half with one half transferred to 366 
cold storage solution and then further cut into smaller pieces (~120 mg) which were then 367 
stored in UW storage solution at ~2˚C. The other half of the heart tissue was also cut into 368 
sections (~120 mg) which were stored in a humidified atmosphere at 37˚C by suspension 369 
above saline in sealed Eppendorf tubes. At various times the tissues were then frozen 370 
using Wollenberger clamps at LN2 temperature and stored at -80˚C until analysis.  371 
To measure the core and surface temperature and tissue succinate of the porcine 372 
heart following rapid retrieval and back-table flush the pig was anaesthetised and 373 
euthanized as described above. After circulatory arrest was confirmed the thoracic cavity 374 
was then rapidly accessed through an incision in the diaphragm and heart was rapidly 375 
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retrieved by division of the great vessels. On removal from the thoracic cavity, a ‘time-376 
zero’ surface wedge and core needle biopsy were immediately taken and clamp frozen in 377 
liquid nitrogen. The core and surface temperature probes (K-type thermocouple, Hanna 378 
Instruments, Bedfordshire) were then inserted into the heart. The core temperature probe 379 
was inserted into the septum using a hollow biopsy needle. A small incision was made in 380 
the surface of the right ventricle in which the surface probe was inserted and sutured in 381 
place. This step took between 1-2 minutes to complete. Temperature recording was then 382 
commenced and the heart was submerged in a pre-prepared dish of slushed ice and UW 383 
solution. The temperature was recorded every second by a digital data-logger connected 384 
to the temperature probe (EL-USB-2 LC, Lascar Electronics, Wiltshire). A 14G French 385 
cannula was used to flush the coronary circulation with cold UW solution. A third 386 
temperature probe was used to measure the temperature of the solution as it entered the 387 
heart. The coronary sinuses at the base of the aorta were alternately cannulated and 388 
effective flushing of the circulation could be directly observed by flushing of blood with 389 
preservation solution in the surface coronary vessels. The time taken to flush the heart 390 
with 500 mL cold UW solution was recorded in each case. Further surface wedge and 391 
core-needle biopsies were taken at 6, 12 and 30 minutes.  392 
 393 
Human heart experiments. Human donation after brainstem death (DBD) donors 394 
undergoing abdominal multi-organ retrieval but for whom cardiothoracic organs had been 395 
declined for transplantation were identified (Supplementary Table 3). Appropriate 396 
consent for research was obtained from the donor families. A thoracotomy was performed 397 
as a routine part of the abdominal organ retrieval procedure, thus allowing a sample (~20-398 
30 g) of myocardium from the apex of the still-beating heart to be removed at the same 399 
time as exsanguination and cross clamp of the donor, during organ retrieval. The heart 400 
tissue was frozen in Wollenberg clamps, taking <5s to go from the beating oxygenated 401 
heart to frozen sample. After this base line sample, further samples (~120 mg) were 402 
removed, maintained at either 37˚C or ~2˚C as described for the pig tissue, and at various 403 
times frozen and stored at -80˚C.  404 
 405 
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Tissue extraction and metabolite analysis by liquid chromatography coupled to 406 
mass spectrometry (LC-MS). Frozen tissue samples were weighed into Precellys tubes 407 
prefilled with ceramic beads (Stretton Scientific Ltd., Derbyshire, UK), and an exact 408 
volume of extraction solution (50% methanol, 30% acetonitrile and 20% water) was 409 
added to obtain 40 mg specimen per mL of extraction solution thus allowing for 410 
comparisons between experimental conditions for the same metabolite. Samples were 411 
lysed using a Precellys®24 tissue homogeniser (Bertin Corp, Rockville, MD 20850, 412 
USA. 5500 rpm 15 seconds x 2) and then centrifuged (16,162 x g for 10 min at 4°C). The 413 
supernatant was transferred to glass vials (Microsolv Technology Corp., Leland, NC 414 
28451, USA) and stored at -80°C until LC-MS analysis. 415 
LC-MS analyses were performed on a Q Exactive Orbitrap (Thermo Scientific) 416 
mass spectrometer coupled to an Ultimate 3000 RSLC system (Dionex). The liquid 417 
chromatography system was fitted with either a ZIC-HILIC column (150 mm × 4.6 mm) 418 
or a ZIC-pHILIC column (150 mm × 2.1 mm) and respective guard columns (20 mm × 419 
2.1 mm) (all Merck, Germany). The metabolites were eluted with previously described 420 
gradients23. The mass spectrometer was operated in full MS and polarity switching mode. 421 
Samples were randomised in order to avoid bias due to machine drift and processed 422 
blindly. The acquired spectra were analysed using XCalibur Qual and and XCalibur Quan 423 
Browser software (Thermo Fisher Scientific) by referencing to an internal library of 424 
compounds. Absolute quantification of selected metabolites was performed by 425 
interpolation of the corresponding standard curve obtained from serial dilutions of 426 
commercially available standards (Sigma Aldrich) running with the same batch of 427 
samples. All the extractions and analyses were done under the same conditions and 428 
relative to the same internal standard. The NADH/NAD+, lactate/pyruvate and 429 
succinate/fumarate ratios are presented as relative changes in the ratio of the ion current 430 
for these metabolites, which is proportional to, but not the same as, the true ratio of the 431 
metabolite levels.  432 
LC-MS/MS analysis of succinate and malonate from pig, mouse and human 433 
temperature studies and fumarate delivery from bis-acetoxymethyl fumarate in cells was 434 
performed using an LCMS-8060 mass spectrometer (Shimadzu, UK) with a Nexera X2 435 
UHPLC system (Shimadzu, UK). Samples were stored in a refrigerated autosampler (4 436 
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°C) upon injection of 5 μl into a 15 μl flow through needle. Separation was achieved 437 
using a SeQuant® ZIC®-HILIC column (3.5 μm, 100 Å, 150 x 2.1 mm, 30 °C column 438 
temperature; MerckMillipore, UK) with a ZIC®-HILIC guard column (200 Å, 1 x 5mm). 439 
A flow rate of 200 μl/min was used with mobile phases of A) 100 mM ammonium 440 
acetate (pH 6.9) and B) 100% acetonitrile. A gradient of 0-0.1 min, 80% MS buffer B; 441 
0.1-4 min, 80%-20% B; 4-10 min, 20% B, 10-11 min, 20%-80% B; 11-15 min, 80% B 442 
was used. The mass spectrometer was operated in negative ion mode with multiple 443 
reaction monitoring (MRM) and spectra were acquired using Labsolutions software 444 
(Shimadzu, UK), with compound quantities calculated from relevant standard curves 445 
(succinate, malonate or fumarate) in MS extraction buffer and comparing against 13C-446 
succinate (for succinate and fumarate) or 13C-malonate (for malonate) internal standards. 447 
Metabolomic data have been uploaded  as study MTBLS1085 to MetaboLights 448 
(https://www.ebi.ac.uk/metabolights). 449 
 450 
Tissue analysis for ATP/ADP ratio. ATP and ADP concentrations were measured using 451 
a Luciferase based assay 24. Frozen tissue samples were homogenised in ice-cold 452 
perchloric acid extractant (3% v/v HClO4, 2 mM Na2EDTA, 0.5% Triton X-100). The 453 
supernatant was diluted to a concentration of 1 mg frozen tissue /ml. Samples, ATP and 454 
ADP standards were pH neutralized using a potassium hydroxide solution (2 M KOH, 455 
2 mM Na2EDTA, 50 mM MOPS), vortexed until formation of a white precipitate 456 
(KClO4), then centrifuged (17, 000 X g for 1 min at 4°C). For ADP measurements, 250 457 
µl neutralised sample supernatant was mixed with 250 µl ATP sulfurylase assay buffer 458 
(20 mM Na2MoO4, 5 mM GMP, 0.2 U ATP sulfurylase (New England Biolabs), in Tris-459 
HCl buffer (100 mM Tris-HCl, 10 mM MgCl2 (pH 8.0))), incubated for 30 min at 30oC 460 
with shaking (500 rpm), heated at 100˚C for 5 min and then cooled on ice. Standards (100 461 
µl), samples for ATP measurement (100 µl) or samples for ADP measurement (200 µl) 462 
(in duplicate) were added to 400 µl Tris-acetate (TA) buffer (100 mM Tris, 2 mM 463 
Na2EDTA, 50 mM MgCl2, pH 7.75 with glacial acetic acid) in luminometer tubes. 10 µl 464 
pyruvate kinase solution (100 mM PEP, 6 U pyruvate kinase suspension (Sigma # 465 
P1506)) were added to one set of samples for ADP measurement and incubated for 30 466 
min at 25°C in the dark to convert ADP to ATP. The other duplicate tube (without 467 
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addition of pyruvate kinase solution) served as an ADP ‘blank’ value. The samples were 468 
then all assayed for ATP content in a Berthold AutoLumat Plus luminometer by addition 469 
of 100 µl Luciferase/Luciferin Solution (7.5 mM DTT, 0.4 mg/ml BSA, 1.92 µg 470 
luciferase/ml (SIGMA #L9506), 120 µM D-luciferin (SIGMA # L9504), made in TA 471 
buffer (25% v/v glycerol)), delivered via auto injection, protected from light. 472 
Bioluminescence of the ATP- dependent luciferase activity was measured for 45 s post 473 
injection and the data quantified against standard curves. 474 
 475 
Glycogen assay. The glycogen assay protocol was adapted from25, measuring the 476 
production of NA(D)PH during the oxidation of glycogen-derived glucose to 6-477 
phosphogluconate. Frozen tissue (5-10 mg) was minced finely before being treated with 478 
250 µl hot acid (2 M HCl; 100°C) or alkali (2 M NaOH; 100°C) to hydrolyse glycogen or 479 
as an unhydrolysed control respectively (100 °C, 1 h, vigorous shaking every 10 min). 480 
Samples were subsequently cooled to RT and neutralised to pH 7 with either 2 M NaOH 481 
or HCl and the addition of 500 µl 400 mM Tris (pH 7.4). Neutralised samples were 482 
vortexed before centrifuging (17,000 x g, 10 min, RT). 60 µl of sample supernatant was 483 
plated in duplicate in a 96-well plate together with a glucose standard curve (0,10, 20, 40, 484 
80, 160 µg glucose/ml). 200 µl glucose assay reagent (G3293, Sigma) was added to each 485 
well and the plate incubated (5 min, RT) prior to measuring absorbance at 340 nm in a 486 
Spectramax Plus 384 plate reader (Molecular Devices, UK). The average absorbance of 487 
each sample was interpolated using the standard curve and multiplied by the final volume 488 
after pH adjustment to give µg of glycogen (or glucose for NaOH control) in original 489 
sample. This was divided by the weight of tissue added and the NaOH control was 490 
subtracted from the HCl sample to give µg glycogen per mg frozen tissue. 491 
 492 
Synthesis of Bis(acetoxymethyl)succinate. 493 
 494 
 495 
Bis(acetoxymethyl)succinate (202 mg, 0.769 mmol) was prepared in 91% yield from 496 
succinic acid (100 mg, 0.847 mmol) in a similar way to Ehinger et al.,17 except 497 
acetonitrile was used as solvent and after 16 h reaction the solvent was evaporated and 498 
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the crude mixture purified by column chromatography [SiO2, hexane-ethyl acetate (7:3)]. 499 
Rf [SiO2, hexane-ethyl acetate (7:3)] = 0.24. νmax (ATR): 1751 (CO) cm-1. δH (400 MHz, 500 
CDCl3): 5.75 (4H, s, OCH2O), 2.71 (4H, s, CH2CO2), 2.12 (6H, s, CH3). δC (126 MHz, 501 
CDCl3): 170.93 (2C, s, CO), 169.71 (2C, s, CO), 79.38 (2C, s, CH2O), 28.66 (2C, s, 502 
CH2CO), 20.80 (2C, s, CH3). LRMS (ESI
+): 285 (MNa+, 100%). HRMS (ESI+): 503 
285.0579. C10H14NaO8
+ requires (MNa+), 285.0581. 1H NMR and 13C NMR data agree 504 
with literature 17. The original data has been deposited 505 
at http://dx.doi.org/10.5525/gla.researchdata.646.  506 
 507 




Bromomethyl acetate (300 μl, 3.06 mmol, 2.2 eq) was added to a solution of fumaric acid 512 
(161 mg, 1.39 mmol, 1.0 eq) and diisopropylamine (605 μl, 3.47 mmol, 2.5 eq) in dry 513 
acetonitrile (8 ml) cooled to 0 °C under argon. The solution was allowed to warm to room 514 
temperature, stirred overnight, concentrated under vacuum and purified by column 515 
chromatography [SiO2, hexane-ethyl acetate (80:20) to (50:50)] to give the bis-AM ester 516 
as a white solid (310 mg, 86%). Rf [SiO2, hexane-ethyl acetate (7:3)] = 0.31. M.p. 89-517 
91°C. νmax (ATR)/cm-1: 1755 (CO2), 1728 (CO2), 977 (C=C). δH (400 MHz: CDCl3): 2.12 518 
(6H, s, CH3), 5.84 (CH2), 6.92 (CH). δC (100 MHz: CDCl3): 20.76 (CH3), 79.80 (CH2), 519 
133.98 (CH), 163.27 (C), 169.51 (C). HRMS (ESI+): 283.0423. C10H12NaO8 requires 520 
(MNa+), 283.0424. The original data have been deposited 521 
at http://dx.doi.org/10.5525/gla.researchdata.646. 522 
 523 
Troponin measurement. Non-heparinised IVC blood samples were taken immediately 524 
prior to graft harvest. Samples were left for 30 mins at room temperature to ensure 525 
adequate clot propagation, centrifuged (2000 x g for 10 minutes) and serum apportioned 526 
into aliquots and stored at -80°C. Serum troponin-I was measured using a commercially 527 






Seattle, WA, USA) by the Core Biomedical Analysis Laboratory, Addenbrooke’s 529 
Hospital, Cambridge.  530 
 531 
Measurement of mtDNA release. The release of mitochondrial and nuclear DNA into 532 
the circulation was assessed using the droplet digital polymerase chain reaction (ddPCR). 533 
Serum samples were centrifuged (1600 g for 10 min) and the supernatant was then 534 
centrifuged once more (16 000 g for 10 min) and DNA isolated using the DNeasy Blood 535 
kit (QIAGEN) according to the manufacturer’s instructions, with step 3, the addition of 536 
lysis buffer AL, omitted. DNA was quantified using a ‘Nanodrop’ system and diluted to 1 537 
ng/µL in elution buffer. For mtDNA the ND5 gene was assessed using the following 538 
primers: F- CTGCTCTTTCCCAGACGAGG; R- AAGGCCACTTATCACCAGC. For 539 
nuclear DNA the β-actin gene was assessed, using F-540 
ACCTAATTAAACACATCAACTTCCC; R- GACTCAGTGCCAGGTTGTAA. Each 541 
PCR reaction (22 µL) comprised 1 µL (= 1 ng) DNA template, 11 µL ddPCR 542 
Supermix (no dUTP) containing Taq, 314 nM of each primer, and 210 nM of the HEX-543 
ND5 probe (ACACCACCACATCAATCAAATTCTCCTTCA) and of the FAM-β-actin 544 
probe (ATTGCCTTTCTGACTAGGTG) and then made up to 22 µl with H2O. The 545 
BIORAD ddPCR AutoDG was used to generate ddPCR droplets and the plate was sealed 546 
at 174˚C before the PCR was run in a BIORAD C1000 Thermo Cycler: 95˚C at 10 min 547 
followed by 40 cycles of 30 sec at 95˚C and 1 min at 58˚C and then 95˚C at 10 min. After 548 
completion of the PCR, the fluorescence of the FAM and HEX probes was measured 549 
using the BIORAD QX200 Droplet Reader and analysed using the BIORAD Quantilife 550 
software and Excel. 551 
 552 
QPCR assay for mtDNA damage. Quantitative PCR to detect murine mitochondrial 553 
DNA lesions was based on26 and performed using following primers at 10 µM: forward 554 
primer FWD: 5’-GCC AGC CTG ACC CAT AGC CAT AAT-3’. Reverse primer for the 555 
long 10090 bp PCR product: REV: 5’-GAG AGA TTT TAT GGG TGT AAT GCG G-3’. 556 
Reverse primer for the short 127 bp PCR product: REV: 5’- GCC GGC TGC GTA TTC 557 
TAC GTT A -3’. Sample DNA was extracted using the QIAmp blood and tissue kit 558 
following the provided instructions. QPCR was performed on 15 ng DNA in 35 µl 559 
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reactions on a PCR thermocycler (Biometra). 1 U TaKaRa LA Taq was used per reaction. 560 
PCR master mix was prepared following the TaKaRa LA Taq instructions. Linearity of 561 
the PCR reaction was confirmed for each sample by running a 1:2 diluted sample 562 
simultaneously. Cycling parameters for the short reaction were 94ºC for 5 minutes 563 
followed by 16 cycles of 94ºC for 30s, 64ºC for 45s, 72ºC for 45s, followed by 72ºC for 564 
10 minutes. Conditions for the long amplification were 94ºC for 5 minutes followed by 565 
18 cycles of 94ºC for 15s and 64ºC for 12 minutes, followed by 72ºC for 10 minutes. The 566 
PCR reaction was confirmed on 1% agarose gels and concentrations of the PCR product 567 
were determined by measuring the emission of the samples at 488 nm and excitation at 568 
525 nm after picogreen addition at 1:200 dilution.  569 
 570 
Cell culture. C2C12 mouse myoblast cells were plated at 300,000 cells/well in 6-well 571 
plates and left to adhere overnight. The following day, cells were treated with 0 (DMSO 572 
vehicle control), 0.25, 0.5 or 1 mM fumarate-AM diester for 30 min at 37 °C. Cells were 573 
washed 4 times with ice-cold PBS prior to extracting with 500 µl extraction buffer 574 
containing 13C-succinate internal standard for 15 min on dry ice. Cells were scraped and 575 
transferred to microcentrifuge tubes prior to agitating (15 min, 4 °C, 1000 rpm), then 576 
incubating (-20 °C, 1 h). Samples were centrifuged (17,000 x g, 10 min, 4 °C), the 577 
supernatant transferred to fresh microcentrifuge tubes and recentrifuged (17,000 x g, 10 578 
min, 4 °C). The resulting supernatant was transferred to glass MS vials and stored at -80 579 
°C until analysis by LC-MS/MS. Fumarate levels were determined by interpolation of a 580 
fumarate standard curve and normalised to cellular protein by BCA assay of a parallel 581 
treated plate. 582 
 583 
Statistics and experimental design. All data in figures are presented as mean values ± 584 
SEM unless otherwise stated. Statistical analysis was performed between two groups 585 
using Student’s t-test with sometimes using Sidak’s post-test for multiple comparisons, 586 
and between multiple groups by one-way analysis of variance (ANOVA) or two-way 587 
ANOVA with Bonferroni’s or Tukey’s multiple comparison testing. A P value of less 588 
than 0.05 was considered significant. 589 
 590 
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Figure legends 635 
 636 
Fig. 1 | The cardiac ATP/ADP ratio during WI and CI a, A schematic illustrating the 637 
experimental design mimicking ischaemia during transplantation. The whole mouse heart 638 
(~150 – 180 mg), or sections from the transected apex of the pig or human heart (~120 639 
mg) were either immediately clamped frozen at liquid nitrogen temperature to generate a 640 
baseline sample under fully oxygenated “normoxic” conditions, or incubated to induce 641 
warm ischaemia (WI, 37°C) or cold ischaemia (CI) (~2°C ) for the indicated times prior 642 
to freeze clamping. Tissues were then extracted and metabolites assayed ATP and ADP 643 
were determined in heart tissue after various times of WI or CI. b-d, The ATP/ADP ratio 644 
for b mouse, c pig and d human. e-g, The sum of ATP and ADP (nmol/mg wet weight) 645 
for e mouse, f pig and g human. Data are means ± SEM, N = 5 - 11 (mouse), 5 (pig), 4 646 
(human).  647 
 648 
Fig. 2 | Volcano plots of metabolites that change significantly between 30 min WI 649 
and CI. Volcano plots showing -log10 of the adjusted p value plotted against the Log2 of 650 
the fold-change in metabolite abundance between 30 min WI and 30 min CI for a mouse, 651 
b pig and c human. Fold-changes and p-values were calculated using the Limma package 652 
with R. Metabolites that changed in the same way in all three species are in red. 653 
Metabolites that changed in the same way in two of the species but were not detected, or 654 
did not change markedly, in the third are in green. Proprionylcarnitine, propcarn; acetyl 655 
carnitine, acetylcarn; succinyl adenosine, succaden; 3-hydroxybutyrate, 3HB; 656 
pyroglutamic acid, pyroglu; cysteine, cys.  657 
Fig. 3 | Succinate levels in the heart during WI and CI. a-d, Fold change in succinate 658 
abundance under WI or CI, relative to normoxic heart tissue in a, d mouse (n = 6), b pig 659 
(n = 4) c human (n = 4). Significant difference between groups were measured by two 660 
way ANOVA with multiple comparisons at individual points by Sidak test (* P < 0.05, 661 
** P < 0.01 *** P < 0.001, **** P < 0.0001). e, Absolute succinate concentrations as 662 
described in a – d. f-h, Relative change in succinate/fumarate ratio under WI or CI, 663 
compared to normoxic heart tissue. These data are presented as relative changes in the 664 
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ratio of the ion current for these metabolites, which is proportional to, but not the same 665 
as, the true ratio of the metabolite levels.  666 
Fig. 4 | Preventing the pathological consequences of succinate metabolism during 667 
heart transplantation. a, Change in surface and core temperature of the porcine heart 668 
during back-table flush with 500 mL cold UW solution. Following cross clamp and rapid 669 
retrieval from the euthanised pig, the heart was immediately flushed with cold 670 
preservation solution via the aortic root cannula in conjunction with immersion in a bowl 671 
containing slushed ice. The mean temperature (n = 4), calculated at 10 s intervals, is 672 
shown ± SEM (shaded area). The labelled inset image shows the pig heart lifted from the 673 
ice slush to show the temperature probes. b, Change in surface and core tissue succinate 674 
of the porcine heart treated as described in a. Core and surface tissue biopsies were taken 675 
at 0, 6, 12 and 30 minutes and clamp frozen in liquid nitrogen. Tissue succinate 676 
concentration was then measured by LC-MS/MS (n = 3 ± SEM). *P < 0.05, by a two-way 677 
ANOVA with Sidak's multiple comparison test. c, Succinate concentration in the mouse 678 
heart after standard retrieval and then 30 min CIT (‘Isch.’), after standard retrieval and 679 
then 30 min CIT and anastomosis (‘Isch. + Impl.’), and finally measured after 5 min 680 
reperfusion (‘Reper.’). Data mean ± SEM (n = 3-4). Compared to control (Cont.) by one-681 
way ANOVA with Bonferroni multiple comparisons tests (***P < 0.001, ****P < 682 
0.0001). d, Schematic of heterotopic heart transplantation in mice, incorporating 683 
exposure to a further 12 min WI after retrieval, followed by cold storage for 30 min. e-g, 684 
Hearts retrieved by a standard protocol, were infused with DMM (3.4 mg) or saline 685 
immediately prior to administration of cardioplegia solution and then exposed to 12 min 686 
WI, and then cold stored for 30 min, or were infused with cardioplegia solution ± AMS 687 
(3.2 mg), followed by cold storage for 30 min. All hearts were then transplanted 688 
heterotopically into recipients and 24 h later serum troponin e, mtDNA f, or 689 
mtDNA/nDNA ratio g, were measured. h, mtDNA damage in the donor heart was 690 
measured 24 h after transplantation by a PCR assay in which the greater the ratio of 691 
amplification the less damage to the mtDNA. (n = 4 - 24 ± SEM). * P < 0.05, **P < 0.01, 692 
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